12:00 AM
 | 
Dec 03, 2001
 |  BioCentury  |  Strategy

Valuing Genomica by its cash

Exelixis Inc.'s acquisition of Genomica Corp. will provide some bioinformatics for managing clinical trials. But it appears that the purchase will play a more immediate and pivotal role as a source of cash to help fund EXEL's movement downstream.

EXEL acquired GNOM essentially for free, trading $110 million in stock for GNOM's $110.8 million in cash and investments. The acquisition followed GNOM's announcement earlier this year...

Read the full 318 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >